Yi Yongxiang, Han Jianbo, Zhao Liang, Wang Chunying, Fang Yuan, Wei Qiang, Hu Liang, Liu Junmao, Zhang Yufeng, Wang Lili
1 Department of Hepatobiliary Surgery, the Second Hospital of Nanjing, Affiliated to Southeast University, Nanjing 210003, China ; 2 Department of Hepatic Internal Medicine, Xuzhou Hospital for Infectious Diseases, Xuzhou 221004, China ; 3 Department of Immunotherapy, 4 Department of Interventional Ultrasound, the Second Hospital of Nanjing, Affiliated to Southeast University, Nanjing 210003, China.
Chin J Cancer Res. 2015 Dec;27(6):597-603. doi: 10.3978/j.issn.1000-9604.2015.12.07.
To induce and collect tumor-derived autophagosomes (DRibbles) from tumor cells as an antitumor vaccine by inhibiting the functions of proteasomes and lysosomes.
Dendritic cells (DCs) generated from peripheral blood mononuclear cell (PBMC) of hepatocellular carcinoma (HCC) patients were cocultured with DRibbles, and then surface molecules of DCs, as well as surface molecules on DCs, were determined by flow cytometry. Meanwhile, immune responses of the DCs-DRibbles were examined by mixed lymphocyte reactions.
DRibbles significantly induced the expression of CD80, CD83, CD86 and HLA-DR on DCs. The enzyme-linked immunosorbnent assay (ELISA) showed that IFN-γ levels after vaccination increased than before in most patients, but CD8+ proportion of PBMC increased only in nine patients. Higher levels of IFN-γ were detected in the CD8+ cells than CD4+ T cells. These results suggested that DCs-DRibbles vaccine could induce antigen-specific cellular immune response on HCC and could prime strong CD8+ T cell responses, supporting it as a tumor vaccine candidate.
Our results demonstrate that HCC/DRibbles-pulsed DCs immunotherapy might be deployed as an effective antitumor vaccine for HCC immunotherapy in clinical trials.
通过抑制蛋白酶体和溶酶体的功能,从肿瘤细胞中诱导并收集肿瘤来源的自噬体(DRibbles)作为抗肿瘤疫苗。
将肝癌(HCC)患者外周血单个核细胞(PBMC)产生的树突状细胞(DC)与DRibbles共培养,然后通过流式细胞术检测DC的表面分子以及DC上的表面分子。同时,通过混合淋巴细胞反应检测DC-DRibbles的免疫反应。
DRibbles显著诱导DC上CD80、CD83、CD86和HLA-DR的表达。酶联免疫吸附测定(ELISA)显示,大多数患者接种疫苗后的IFN-γ水平比之前升高,但仅9例患者外周血单个核细胞的CD8+比例增加。在CD8+细胞中检测到的IFN-γ水平高于CD4+T细胞。这些结果表明,DC-DRibbles疫苗可诱导肝癌患者产生抗原特异性细胞免疫反应,并可引发强烈的CD8+T细胞反应,支持其作为肿瘤疫苗候选物。
我们的结果表明,HCC/DRibbles脉冲DC免疫疗法可能在临床试验中作为一种有效的抗肿瘤疫苗用于肝癌免疫治疗。